# Bowang Pharmaceutical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bowang-pharmaceutical

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Total disclosed funding: $104M
- Latest round: Series A (Nov 1, 2023)
- Investors on record: 9

## About

Established in 2021 and based in Shanghai, China, Bowang Pharmaceutical is an RNAi drug R&D platform dedicated to the development of a new generation of RNAi drugs. In November 2023, it raised CNY 300 million in series A+ funding led by new investor CS Capital, with participation from new investors GSR United Capital, Huagai Capital and returning investor Trinity Innovation Fund.

The company is dedicated to the development of siRNA (Small interfering RNA) drugs. Its products are used in the field of cardiovascular diseases, rare diseases, hepatitis B, autoimmune, neurological disorders.


The company will use the series A+ funding to advance the global development of four clinical pipelines, the discovery of multiple preclinical drug candidate molecules (PCCs), and the iterative upgrading of the modification technology platform and the extrahepatic delivery technology platform. In addition, its four oligonucleic acid programs are expected to enter clinical phase 2 in early 2024.

## Funding rounds

- Series A, Nov 1, 2023, $41M — Huagai Capital, CS Capital, GSR United Capital, Trinity Innovation Fund
- Series A, Mar 23, 2022, $63M — GSR Ventures, CPE Funds Management, Loyal Valley Capital, Tao Capital, Trinity Innovation Fund
- Angel, Apr 27, 2021 — Apricot Capital

## Investors

- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Angel
- GSR Ventures (https://capitalatlas.ai/funds/gsr-ventures) — Series A
- CPE Funds Management (https://capitalatlas.ai/funds/cpe-funds-management) — Series A
- Loyal Valley Capital (https://capitalatlas.ai/funds/loyal-valley-capital) — Series A
- Tao Capital (https://capitalatlas.ai/funds/tao-capital) — Series A
- Trinity Innovation Fund (https://capitalatlas.ai/funds/trinity-innovation-fund) — Series A
- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series A
- CS Capital — Series A
- GSR United Capital (https://capitalatlas.ai/funds/gsr-united-capital) — Series A